Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2004

Yang Zhibo, Bagheri-Yarmand Rozita, Wang Rui-An, Adam Liana, Papadimitrakopoulou Vali Vassiliki, Clayman Gary L, El-Naggar Adel, Lotan Reuben, Barnes Christopher J, Hong Waun Ki, Kumar Rakesh

Abstract excerpt

PURPOSE: Abnormalities in the expression and signaling pathways downstream of the epidermal growth factor receptor (EGFR) contribute to the progression, invasion, and maintenance of the malignant phenotype in human cancers, including those of the head and neck and breast. Accordingly, agents such...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CSK Tyrosine-Protein Kinase
Share to Cytoskeleton

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epidermal Growth Factor

Share to Gefitinib

Share to p21-Activated Kinases

Share to Quinazolines

Share to src-Family Kinases

Share to Vinculin

Source

Identifiers

PMID: 14760089
DOI: 10.1158/1078-0432.ccr-0382-03

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-14760089-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.PMID 14760089Read ↗

Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).Semantic proximity Read ↗

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.Semantic proximity Read ↗

ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines.Semantic proximity Read ↗

PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.Semantic proximity Read ↗

GEP100/Arf6 Is Required for Epidermal Growth Factor-Induced ERK/Rac1 Signaling and Cell Migration in Human Hepatoma HepG2 CellsSemantic proximity Read ↗

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.Semantic proximity Read ↗

Epidermal growth factor receptor dependence in human tumors: more than just expression?Semantic proximity Read ↗

Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastomaSemantic proximity Read ↗

The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.Semantic proximity Read ↗

Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.Semantic proximity Read ↗

Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.